under protocol number 7051-ONC-101 entitled "A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer" (as it may be amended from time to time by Sponsor, the "Protocol"; the performance of the Protocol at all sites is
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
FORMA Therapeutics, Inc.
Start Date
April 21, 2021
End Date
October 24, 2025
Administered By
Duke Cancer Institute
Awarded By
FORMA Therapeutics, Inc.
Start Date
April 21, 2021
End Date
October 24, 2025